• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Scienture Holdings Inc.

    8/20/25 7:21:15 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care
    Get the next $SCNX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Scienture Holdings Inc.

    (Name of Issuer)


    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)


    80880X104

    (CUSIP Number)


    08/14/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    80880X104


    1Names of Reporting Persons

    Scoggin International Fund Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    150,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    150,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    150,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.01 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  The percentage of Common stock reported herein as being beneficially owned by the Reporting Persons reflects 16,131,180 shares of Common stock outstanding as of August 12, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025.


    SCHEDULE 13G

    CUSIP No.
    80880X104


    1Names of Reporting Persons

    Scoggin Management LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    150,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    150,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    150,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.01 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  The percentage of Common stock reported herein as being beneficially owned by the Reporting Persons reflects 16,131,180 shares of Common stock outstanding as of August 12, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025.


    SCHEDULE 13G

    CUSIP No.
    80880X104


    1Names of Reporting Persons

    Scoggin GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    150,000.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    150,000.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    150,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.01 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  The percentage of Common stock reported herein as being beneficially owned by the Reporting Persons reflects 16,131,180 shares of Common stock outstanding as of August 12, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025.


    SCHEDULE 13G

    CUSIP No.
    80880X104


    1Names of Reporting Persons

    Curtis Schenker
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    150,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    150,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    150,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.01 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Comprised of shares of Common stock held by Scoggin International Fund Ltd. Curtis Schenker is a co-managing member of Scoggin GP LLC, which is the general partner of Scoggin Management LP, the investment manager of Scoggin International Fund Ltd. The percentage of Common stock reported herein as being beneficially owned by the Reporting Persons reflects 16,131,180 shares of Common stock outstanding as of August 12, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025.


    SCHEDULE 13G

    CUSIP No.
    80880X104


    1Names of Reporting Persons

    Craig Effron
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    150,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    150,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    150,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.01 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Comprised of shares of Common stock held by Scoggin International Fund Ltd. Craig Effron is a co-managing member of Scoggin GP LLC, which is the general partner of Scoggin Management LP, the investment manager of Scoggin International Fund Ltd. The percentage of Common stock reported herein as being beneficially owned by the Reporting Persons reflects 16,131,180 shares of Common stock outstanding as of August 12, 2025, as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Scienture Holdings Inc.
    (b)Address of issuer's principal executive offices:

    20 Austin Blvd, Commack, NY 11725
    Item 2. 
    (a)Name of person filing:

    Scoggin International Fund Ltd., Scoggin Management LP, Scoggin GP LLC, Curtis Schenker, and Craig Effron
    (b)Address or principal business office or, if none, residence:

    The principal business address of Scoggin International Fund Ltd. is c/o Mourant Ozannes Corporate Services (Cayman) Ltd., 94 Solaris Avenue, Camana Bay, P.O. Box 1348, Grand Cayman, KY1-1108, Cayman Islands The principal business address of each other Reporting Person is 654 Madison Avenue, 10th Floor, New York, NY 10065.
    (c)Citizenship:

    Scoggin International Fund Ltd. - Cayman Islands Scoggin Management LP and Scoggin GP LLC - Delaware Curtis Schenker and Craig Effron - United States of America
    (d)Title of class of securities:

    Common Stock, par value $0.00001 per share
    (e)CUSIP No.:

    80880X104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Scoggin International Fund Ltd. - 150,000 Scoggin Management LP - 150,000 Scoggin GP LLC - 150,000 Curtis Schenker - 150,000 Craig Effron - 150,000
    (b)Percent of class:

    Scoggin International Fund Ltd. - 0.01% Scoggin Management LP - 0.01% Scoggin GP LLC - 0.01% Curtis Schenker - 0.01% Craig Effron - 0.01%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Scoggin International Fund Ltd. - 150,000 Scoggin Management LP - 150,000 Scoggin GP LLC - 150,000 Curtis Schenker - 150,000 Craig Effron - 150,000

     (ii) Shared power to vote or to direct the vote:

    Scoggin International Fund Ltd. - 0 Scoggin Management LP - 0 Scoggin GP LLC - 0 Curtis Schenker - 150,000 Craig Effron - 150,000

     (iii) Sole power to dispose or to direct the disposition of:

    Scoggin International Fund Ltd. - 150,000 Scoggin Management LP - 150,000 Scoggin GP LLC - 150,000 Curtis Schenker - 0 Craig Effron - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Scoggin International Fund Ltd. - 0 Scoggin Management LP - 0 Scoggin GP LLC - 0 Curtis Schenker - 150,000 Craig Effron - 150,000

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit B
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Scoggin International Fund Ltd.
     
    Signature:/s/ Craig Effron
    Name/Title:Craig Effron/Co-Managing Member
    Date:08/20/2025
     
    Scoggin Management LP
     
    Signature:/s/ Craig Effron
    Name/Title:Craig Effron/Co-Managing Member
    Date:08/20/2025
     
    Scoggin GP LLC
     
    Signature:/s/ Craig Effron
    Name/Title:Craig Effron/Co-Managing Member
    Date:08/20/2025
     
    Curtis Schenker
     
    Signature:/s/ Curtis Schenker
    Name/Title:Curtis Schenker
    Date:08/20/2025
     
    Craig Effron
     
    Signature:/s/ Craig Effron
    Name/Title:Craig Effron
    Date:08/20/2025
    Exhibit Information

    Exhibit A. Joint Filing Agreement. Exhibit B. Item 8 Statement.

    Get the next $SCNX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCNX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

    Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (NASDAQ:SCNX) ("Scienture" or the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 3,225,000 shares of common stock at an offering price of $1.20 per share, in a registered direct offering. The gross proceeds for the offering are expected to be approximately $3.9 million bef

    8/14/25 9:00:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

    COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the shipment of launch quantities of Arbli™ (losartan potassium) Oral Suspension, 10 mg/mL to its 3PL/Distribution Center for the intended commercial launch of the product. This shipment marks a major milestone accomplishment for Scienture, which has agreements in place for the distribution of the product through wholesa

    8/13/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

    Commack, NY, July 24, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company") a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that its board of directors has approved a bridge funding raise of up to an aggregate amount of $3 million, of which it has secured approximately $1.2 million, through the issuance of shares of the Company's common stock to institutional or accredited investors. The bridge funding does not include any other obli

    7/24/25 5:12:00 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    $SCNX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Scienture Holdings Inc.

    SCHEDULE 13G - Scienture Holdings, Inc. (0001382574) (Subject)

    8/20/25 7:21:15 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    Scienture Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Scienture Holdings, Inc. (0001382574) (Filer)

    8/15/25 5:10:42 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    SEC Form 424B5 filed by Scienture Holdings Inc.

    424B5 - Scienture Holdings, Inc. (0001382574) (Filer)

    8/15/25 10:37:17 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care

    $SCNX
    Leadership Updates

    Live Leadership Updates

    View All

    SCIENTURE Announces Executive Leadership Transition

    TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that Suren Ajjarapu, who has served as Chief Executive Officer (CEO) and Chairman of the Board of Directors (BOD), has stepped down from his roles with the Company, with those positions being assumed by the existing, experienced management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani. Shankar Hariharan, P

    5/22/25 8:05:00 AM ET
    $SCNX
    Other Pharmaceuticals
    Health Care